SPRB

SEC source: 0000919574-25-006126 · ownership.xml · nonDerivative · entry 1

Parkman Healthcare Partners LLC · CIK 0001777015 · 10% owner

Martinez Gregory · CIK 0002091748 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,307

F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $17.55 to $18. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-25-020265 · form4-07242025_110718.xml · derivative · entry 1

Ways Kirk · CIK 0001869391 · Director · Interim Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-22

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020270 · form4-07242025_110741.xml · derivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020269 · form4-07242025_110757.xml · derivative · entry 1

SIMPSON CAMILLA V · CIK 0001822557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020268 · form4-07242025_110751.xml · derivative · entry 1

GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020266 · form4-07242025_110758.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020267 · form4-07242025_110706.xml · derivative · entry 1

Barretto-Ko Percival · CIK 0001978654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-25-020261 · form4-07242025_110724.xml · derivative · entry 1

Muralidhar Bali · CIK 0001784138 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 9

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,000

Underlying: Common Stock · 111,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares.

F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares.

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 8

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,100

Underlying: Common Stock · 89,700 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

F4 · balance_after: Represents the aggregate balance of time-based RSUs.

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 6

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,191

F3 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares.

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 5

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 506,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 4

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 395,796

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 3

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 9

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,500

Underlying: Common Stock · 31,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares.

F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 8

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,800

Underlying: Common Stock · 26,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

F4 · balance_after: Represents the aggregate balance of time-based RSUs.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 6

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,339

F3 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 5

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,668

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On December 5, 2022, the Reporting Person was granted 127,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 31,750 RSUs vested, with 11,329 shares being withheld for taxes, resulting in a net issuance of 20,421 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 4

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,918

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 3

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 9

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,500

Underlying: Common Stock · 37,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares.

F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 8

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,500

Underlying: Common Stock · 38,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

F4 · balance_after: Represents the aggregate balance of time-based RSUs.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 6

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,550

F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 5

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 363,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On December 5, 2022, the Reporting Person was granted 149,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 37,250 RSUs vested, with 13,291 shares being withheld for taxes, resulting in a net issuance of 23,959 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 4

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,591

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 3

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 340,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 7

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,800

Underlying: Common Stock · 358,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 2

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,101

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

SEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 1

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 466,121

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · derivative · entry 7

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,400

Underlying: Common Stock · 106,400 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 2

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,809

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

SEC source: 0001415889-24-030001 · form4-12212024_011259.xml · nonDerivative · entry 1

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 212,800 RSUs. 50% or 106,400 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 106,400 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 26,600 shares vested and 9,491 shares were withheld for taxes, resulting in a net issuance of 17,109 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · derivative · entry 7

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,000

Underlying: Common Stock · 154,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock.

F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 2

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 301,828

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

SEC source: 0001415889-24-030000 · form4-12212024_011255.xml · nonDerivative · entry 1

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 308,000 RSUs. 50% or 154,000 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An additional 50% or 154,000 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 38,500 shares vested and 13,737 shares were withheld for taxes, resulting in a net issuance of 24,763 shares.

F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock.

SEC source: 0001415889-24-014495 · form4-05242024_080552.xml · derivative · entry 1

Ways Kirk · CIK 0001869391 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014493 · form4-05242024_080517.xml · derivative · entry 1

SPIEGELMAN DANIEL K · CIK 0001238403 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014492 · form4-05242024_080514.xml · derivative · entry 1

SIMPSON CAMILLA V · CIK 0001822557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014491 · form4-05242024_080524.xml · derivative · entry 1

Muralidhar Bali · CIK 0001784138 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014490 · form4-05242024_080537.xml · derivative · entry 1

GREY MICHAEL G · CIK 0001240122 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014489 · form4-05242024_080535.xml · derivative · entry 1

Barretto-Ko Percival · CIK 0001978654 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001415889-24-014488 · form4-05242024_080531.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

SEC source: 0001209191-24-005075 · doc4.xml · nonDerivative · entry 1

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,550,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.71 to $0.7785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 3

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,015,021

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7110 to $0.7633, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 2

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,375,000

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7105 to $0.7887, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-24-005017 · doc4.xml · nonDerivative · entry 1

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,968,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.8004, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-24-008264 · form4-03182024_080323.xml · derivative · entry 1

Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,800

Underlying: Common Stock · 358,800 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock.

F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.

F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.

SEC source: 0001209191-24-004900 · doc4.xml · nonDerivative · entry 1

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,810,020

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-24-008279 · form4-03182024_080353.xml · derivative · entry 1

Charlton Ralph William III · CIK 0001919397 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,400

Underlying: Common Stock · 106,400 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock.

F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.

F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.

SEC source: 0001415889-24-008270 · form4-03182024_080346.xml · derivative · entry 1

Gharib Samir M. · CIK 0001533302 · PRESIDENT AND CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,000

Underlying: Common Stock · 154,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock.

F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.

F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective.